What question did this study set out to answer?

To evaluate whether co-incident EGFR amplification and PI3K pathway mutations serve as predictive biomarkers for synergistic response to dual EGFR/PI3K inhibition in breast cancer.

June 7, 2025Open Access

EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition

View Full Paper

Ask AI

Bookmark

Authors

DWDavid WisniewskiNational Cancer Institute DVDonna VoellerNational Institutes of Health YAYonit A. AddissieNational Cancer Institute

Discussion

Member takes

Implication

Preclinical study reveals dual EGFR and PI3K inhibition synergistically reduces tumor growth in EGFR-amplified breast cancers with PI3K mutations, highlighting a predictive biomarker combination.

Key Points

To evaluate whether co-incident EGFR amplification and PI3K pathway mutations serve as predictive biomarkers for synergistic response to dual EGFR/PI3K inhibition in breast cancer.
Analyzed genomic and clinical survival data to assess the prevalence of EGFR amplification and concurrent PI3K pathway mutations in breast cancer cohorts.
Tested dual EGFR/PI3K pathway inhibition in vitro using BT20 and MDA-MB-468 cell lines to measure effects on AKT/mTOR signaling, cell viability, and apoptosis.
Assessed in vivo therapeutic efficacy of single-agent versus combination inhibition in a BT20 mouse xenograft model.
EGFR amplification was identified in approximately 1% to 5% of breast cancer cases and correlated with shorter overall survival, with up to 71% of these tumors harboring activating PI3K pathway mutations.
Dual EGFR and PI3K inhibition substantially suppressed downstream AKT and mTOR signaling, synergistically reduced cell viability, and elevated apoptosis in dual-altered BT20 and MDA-MB-468 cells.
While single-agent treatments reduced tumor burden, only dual combination therapy achieved a statistically significant reduction in tumor volume compared to controls in the BT20 xenograft model.

Cite This Study

Wisniewski et al. (2025) studied this question.

synapsesocial.com/papers/6a7c83d57622cda7f36e9c9f https://doi.org/10.1101/2025.06.03.657674

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study reveals dual EGFR and PI3K inhibition synergistically reduces tumor growth in EGFR-amplified breast cancers with PI3K mutations, highlighting a predictive biomarker combination.

EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition

Discussion

Member takes

Implication

Key Points

Cite This Study

EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider